BRPI0414864A - composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida - Google Patents

composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida

Info

Publication number
BRPI0414864A
BRPI0414864A BRPI0414864-9A BRPI0414864A BRPI0414864A BR PI0414864 A BRPI0414864 A BR PI0414864A BR PI0414864 A BRPI0414864 A BR PI0414864A BR PI0414864 A BRPI0414864 A BR PI0414864A
Authority
BR
Brazil
Prior art keywords
combination
mycophenolic acid
pharmaceutical composition
rapamide
mycophenolate sodium
Prior art date
Application number
BRPI0414864-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Dieter Becker
Carsten Buerger
Gilles Feutren
Patrice Guitard
Andrea Kramer
Nicoletta Loggia
Christian-Peter Luftensteiner
J Rg Ogorka
Harald Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0414864A publication Critical patent/BRPI0414864A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0414864-9A 2003-10-03 2004-10-01 composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida BRPI0414864A (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds
PCT/EP2004/010998 WO2005034916A1 (en) 2003-10-03 2004-10-01 Pharmaceutical multiparticulate composition comprising mycophenolic acid or mycophenolate sodium and combination with rapamycin

Publications (1)

Publication Number Publication Date
BRPI0414864A true BRPI0414864A (pt) 2006-11-28

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414864-9A BRPI0414864A (pt) 2003-10-03 2004-10-01 composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida

Country Status (11)

Country Link
US (1) US20070036857A1 (enExample)
EP (1) EP1670437A1 (enExample)
JP (1) JP2007507458A (enExample)
AR (1) AR045957A1 (enExample)
AU (1) AU2004280078B2 (enExample)
BR (1) BRPI0414864A (enExample)
CA (1) CA2538099A1 (enExample)
MX (1) MXPA06003646A (enExample)
PE (1) PE20050755A1 (enExample)
TW (1) TW200520759A (enExample)
WO (1) WO2005034916A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
WO2006086498A2 (en) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
KR20080094788A (ko) * 2006-02-13 2008-10-24 노파르티스 아게 고복용량의 미코페놀산(엠피에이)
CA2669415A1 (en) * 2006-11-14 2008-05-22 Ariad Pharmaceuticals, Inc. Solid dosage form comprising ap23573
AU2008288106B2 (en) * 2007-08-13 2012-03-15 Panacea Biotec Limited Extended release compositions comprising mycophenolate sodium and processes thereof
CN101969931A (zh) * 2008-03-05 2011-02-09 万能药生物有限公司 包含霉酚酸的调节释放药物组合物及其方法
EP2446027A1 (en) * 2009-06-25 2012-05-02 Danisco A/S Protein
EA201270544A1 (ru) * 2009-10-13 2012-09-28 Тева Фармасьютикал Индастриз Лтд. Композиции с отсроченным высвобождением
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2763663B1 (en) * 2011-10-06 2017-12-27 Novartis AG Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin
JP2015533174A (ja) * 2012-10-11 2015-11-19 セラヴィダ,インコーポレイテッド ピロカルピンの医薬製剤
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事(everolimus)之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
US10576076B2 (en) 2015-05-20 2020-03-03 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
JP2020500930A (ja) 2016-11-23 2020-01-16 ノバルティス アーゲー エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法
MX2019010829A (es) * 2017-03-13 2020-02-05 Okava Pharmaceuticals Inc Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos.
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
US20250282721A9 (en) * 2021-12-23 2025-09-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
WO2023224914A1 (en) * 2022-05-16 2023-11-23 Mayo Foundation For Medical Education And Research Assessing and treating caveolinopathy diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
PL177323B1 (pl) * 1993-10-01 1999-10-29 Syntex Inc Kompozycja farmaceutyczna zawierająca mykofenolan mofetylu lub kwas mykofenolowy i sposób wytwarzania kompozycji farmaceutycznej zawierającej mykofenolan mofetylu lub kwas mykofenolowy
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
CN1233169A (zh) * 1996-10-14 1999-10-27 弗·哈夫曼-拉罗切有限公司 一种粉末状制剂的制备工艺
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
JP2005514411A (ja) * 2002-01-10 2005-05-19 ノバルティス アクチエンゲゼルシャフト ラパマイシンおよびその誘導体を含む血管疾患の予防および処置用薬剤送達システム
SI1539157T1 (sl) * 2002-09-18 2013-11-29 Trustees Of The University Of Pennsylvania Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1670437A1 (en) 2006-06-21
JP2007507458A (ja) 2007-03-29
MXPA06003646A (es) 2006-06-05
AU2004280078A1 (en) 2005-04-21
WO2005034916A1 (en) 2005-04-21
TW200520759A (en) 2005-07-01
US20070036857A1 (en) 2007-02-15
CA2538099A1 (en) 2005-04-21
AR045957A1 (es) 2005-11-16
PE20050755A1 (es) 2005-11-28
AU2004280078B2 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
BR0206955A (pt) Ligantes de receptores de canabinóides
BRPI0414492A8 (pt) solvato acetônico do dimetóxi docetaxel e seu processo de preparação
BR0210028A (pt) Agentes antibacterianos
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
EP2266623A3 (en) Prodrugs containing novel bio-cleavable linkers
BR0011448A (pt) Imidazoquinolinas substituìdas por amida
EP2266622A3 (en) Prodrugs containing novel bio-cleavable linkers
GT200200122A (es) Imidazotriazinas
WO2006024479A3 (en) Pharmaceutical multiparticulate compositions comprising mycophenolic acid or mycophenolate sodium and combination compositions with rapamycin
MA30152B1 (fr) Suspension de fexofenadine
EP1875894A3 (fr) Utilisation d'au moins un dérivé C-glycoside à titre d'agent apaisant
DE602007011302D1 (de) Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
BR0300709A (pt) Sal de perindopril e as composições farmacêuticas contendo o mesmo
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
EA200970124A1 (ru) Производные 2-арилиндола в качестве ингибиторов npges-1
GT200100148A (es) Derivados de 4-fenil-piridina.
BR0315139A (pt) Agentes antibacterianos de tetraidroquinolina tricìclica
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
BR0314352A (pt) Indóis 2,7-substituìdos e seu uso como moduladores de 5-ht6
TR200200310T2 (tr) Interlökin-5 inhibe eden 6-azaurasil türevleri.
BRPI0406824A (pt) Indolonaoxazoldinonas antiibacterianas, intermediários para seu preparo e composições farmacêuticas que as contêm
ATE499372T1 (de) Azabenzimidalzolderivate, ihre herstellung und ihre verwendung als antikrebsmittel
BRPI0620229A8 (pt) formulação
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.